Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

115 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Harmonized Outcome Measures for Use in Depression Patient Registries and Clinical Practice.
Gliklich RE, Leavy MB, Cosgrove L, Simon GE, Gaynes BN, Peterson LE, Olin B, Cole C, DePaulo JR Jr, Wang P, Crowe CM, Cusin C, Nix M, Berliner E, Trivedi MH. Gliklich RE, et al. Among authors: cusin c. Ann Intern Med. 2020 Jun 16;172(12):803-809. doi: 10.7326/M19-3818. Epub 2020 May 12. Ann Intern Med. 2020. PMID: 32422056 Review.
Double-blind, proof-of-concept (POC) trial of Low-Field Magnetic Stimulation (LFMS) augmentation of antidepressant therapy in treatment-resistant depression (TRD).
Fava M, Freeman MP, Flynn M, Hoeppner BB, Shelton R, Iosifescu DV, Murrough JW, Mischoulon D, Cusin C, Rapaport M, Dunlop BW, Trivedi MH, Jha M, Sanacora G, Hermes G, Papakostas GI. Fava M, et al. Among authors: cusin c. Brain Stimul. 2018 Jan-Feb;11(1):75-84. doi: 10.1016/j.brs.2017.09.010. Epub 2017 Sep 23. Brain Stimul. 2018. PMID: 29030111 Free PMC article. Clinical Trial.
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Fava M, et al. Among authors: cusin c. Mol Psychiatry. 2020 Jul;25(7):1592-1603. doi: 10.1038/s41380-018-0256-5. Epub 2018 Oct 3. Mol Psychiatry. 2020. PMID: 30283029 Free PMC article.
Correction: Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Fava M, Freeman MP, Flynn M, Judge H, Hoeppner BB, Cusin C, Ionescu DF, Mathew SJ, Chang LC, Iosifescu DV, Murrough J, Debattista C, Schatzberg AF, Trivedi MH, Jha MK, Sanacora G, Wilkinson ST, Papakostas GI. Fava M, et al. Among authors: cusin c. Mol Psychiatry. 2020 Jul;25(7):1604. doi: 10.1038/s41380-018-0311-2. Mol Psychiatry. 2020. PMID: 30617276 Free PMC article.
Time to relapse after a single administration of intravenous ketamine augmentation in unipolar treatment-resistant depression.
Salloum NC, Fava M, Hock RS, Freeman MP, Flynn M, Hoeppner B, Cusin C, Iosifescu DV, Trivedi MH, Sanacora G, Mathew SJ, Debattista C, Ionescu DF, Papakostas GI. Salloum NC, et al. Among authors: cusin c. J Affect Disord. 2020 Jan 1;260:131-139. doi: 10.1016/j.jad.2019.09.017. Epub 2019 Sep 3. J Affect Disord. 2020. PMID: 31494365 Free PMC article.
Exploration of baseline and early changes in neurocognitive characteristics as predictors of treatment response to bupropion, sertraline, and placebo in the EMBARC clinical trial.
Ang YS, Bruder GE, Keilp JG, Rutherford A, Alschuler DM, Pechtel P, Webb CA, Carmody T, Fava M, Cusin C, McGrath PJ, Weissman M, Parsey R, Oquendo MA, McInnis MG, Cooper CM, Deldin P, Trivedi MH, Pizzagalli DA. Ang YS, et al. Among authors: cusin c. Psychol Med. 2022 Oct;52(13):2441-2449. doi: 10.1017/S0033291720004286. Epub 2020 Nov 20. Psychol Med. 2022. PMID: 33213541 Free PMC article. Clinical Trial.
115 results